Skip to main content


You are viewing the new article page. Let us know what you think. Return to old version

Erratum | Open | Published:

Erratum to: Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer

The original article was published in Breast Cancer Research 2012 14:R108


Following publication of our article [1], we noticed two errors in Figure 3. Panel 3C, Con H3K4me2 was an erroneous duplication of panel 3D, Con H3K4me2 and the incorrect image was included for panel 3D, Con H3K9Ac. The results and conclusions are unaffected. The correct figure is given here as Figure 1.

Figure 1

Pargyline promotes inhibitory epigenetic modifications. (A) MCF-7-PELP1 cells and (B) MCF-7-HER2 cells were treated with pargyline (3 mM), and chromatin immunoprecipitation analysis was performed using H3K4me2-specific, H3K9me2-specific or H3K9ac-specific antibodies and the status of epigenetic modifications was analyzed using real-time PCR with the estrogen receptor target gene GREB1C proximal promoter-specific primers (B). Immunohistochemistry analysis of indicated epigenetic marks was done on (C) MCF-7 and (D) MCF-7-PELP1 xenografts that were treated with or without pargyline. Representative images are shown. Quantitation of staining performed as described in Materials and methods. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. PAR, pargyline; PELP1, proline glutamic acid and leucine-rich protein 1.


  1. 1.

    Cortez V, Mann M, Tekmal S, Suzuki T, Miyata N, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Vadlamudi RK: Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res. 2012, 14: R108-10.1186/bcr3229.

Download references

Author information

Correspondence to Ratna K Vadlamudi.

Additional information

The online version of the original article can be found at 10.1186/bcr3229

Authors’ original submitted files for images

Authors’ original file for figure 1

Rights and permissions

Reprints and Permissions

About this article